- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01316354
Effect of Dietary Fibre and Whole Grain on the Metabolic Syndrome
Effect of Arabinoxylan and Beta-glucan Compared With Whole Grain and Whole Meal Bread in Subjects With the Metabolic Syndrome
Sedentary lifestyles and increasing obesity are main causes of the global increase in the prevalence of the metabolic syndrome (Mets) and type 2 diabetic (T2DM). Diet quality, particularly composition of carbohydrate play also a significant role. The glycemic index (GI) describes in relative terms rise of blood glucose after ingestion of carbohydrate-rich food. Purified dietary fibre as β-glucan (BG) has been shown to reduce GI and affect levels of satiety hormones. In contrast, our knowledge of the physiological effects of arabinoxylans (AX), which constitute a substantial part of dietary fibre in cereal products, is limited. The investigators also lack a deeper understanding of the importance of whole grain (whole grain with whole kernels, and purified dietary fibre) in relation to Mets and T2DM.
Hypothesis: The composition of dietary carbohydrates can be designed so that they improve the glycemic and insulinaemic responses and increase satiety feeling. This can be detected in metabolic parameters in subjects with Mets.
The aim of our study is in subjects with Mets to compare the effect of acute consumption of bread rich in (a) purified AX, (b) purified BG, (c) rye bread with whole kernels (RK), with a (d) control group with consumption of white bread (WB).
The primary endpoint is GI. Secondary endpoints are the following items: glycemic load, insulin index, glucose, insulin, glucagon, inflammatory markers, incretins, rate of gastric emptying, and metabolomics. Also satiety feeling will be measured.
This project will improve opportunities for identifying and designing foods with low GI that is particularly suited to people who are at high risk of developing T2DM. The investigators also expect to gain a greater understanding of the metabolic fingerprint, as seen after ingestion of low-GI foods and thereby gain a molecular understanding of how low-GI foods affect health by altering metabolic processes. This will give us a deeper insight into the metabolic processes that are necessary for maintaining normal glucose homeostasis.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8000
- Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
central obesity (Female > 94 cm; Male > 80 cm) with two of the following: -- fasting triglyceride (> 1,7 mmol/L)
- HDL-cholesterol: (Female: < 1,03 mmol/L; Male: < 1,29 mmol/L)
- blood pressure (≥ 130/85 mmHg)
- fasting plasma glucose (≥ 5,6 mmol/L)) Subjects who are in medical treatment with lipid and blood pressure-lowering drugs can continue with their habitual treatment provided that the treatment is stable throughout the trial.
Exclusion Criteria:
- fasting plasma glucose > 7,0 mmol/l
- fasting plasma triglyceride > 5,0 mmol/l
- blood pressure > 160/100 mmHg
- legal incapacity
- endocrine, cardiovascular or kidney disease
- BMI > 38kg/m2
- corticosteroid treatment
- alcohol or drug addiction
- pregnancy or lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Beta-glucan
Bread with purified beta-glucan
|
Bread with 50 g available carbohydrate
|
|
Experimental: Rye kernels
Rye bread with kernels
|
Bread with 50 g available carbohydrate
|
|
Experimental: White bread
|
Bread with 50 g available carbohydrate
|
|
Experimental: Arabinoxylan
Bread with Purified arabinoxylan
|
Bread with 50 g available carbohydrate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Glycaemic index of breads with arabinoxylan and beta-glucan compared with whole grain breads in subject with the metabolic syndrome
Time Frame: 4,5 hours
|
4,5 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic response and satiety
Time Frame: 4,5 hours
|
glycemic load, insulin index, glucose, insulin, incretins, inflammatory markers, rate of gastric emptying, metabolomics, and satiety feeling
|
4,5 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Krishnan S, Hendriks HF, Hartvigsen ML, de Graaf AA. Feed-forward neural network model for hunger and satiety related VAS score prediction. Theor Biol Med Model. 2016 Jul 7;13(1):17. doi: 10.1186/s12976-016-0043-4.
- Nielsen KL, Hartvigsen ML, Hedemann MS, Laerke HN, Hermansen K, Bach Knudsen KE. Similar metabolic responses in pigs and humans to breads with different contents and compositions of dietary fibers: a metabolomics study. Am J Clin Nutr. 2014 Apr;99(4):941-9. doi: 10.3945/ajcn.113.074724. Epub 2014 Jan 29.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERN-BioFunCarb
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Sun Yat-sen UniversityNot yet recruitingMetabolic Syndrome Risk Factors | Metabolic Syndrome (MetS)China
-
Meihua JiThe Luhe Teaching Hospital of the Capital Medical UniversityRecruiting
-
Meihua JiThe Luhe Teaching Hospital of the Capital Medical UniversityEnrolling by invitationMetabolic Syndrome (MetS)China
-
National University Health System, SingaporeRecruitingMetabolic Syndrome | Metabolic Syndrome (MetS)Singapore
-
University of KhartoumMinistry of Higher Education and Scientific Research, Republic of SudanCompletedMetabolic Syndrome in Postmenopausal FemalesSudan
-
Hacettepe UniversityCompletedMetabolic Syndrome | Metabolic Syndrome Obesity | Metabolic Syndrome ParametersTurkey
-
Universidad de los Andes, ChileCompleted
-
University of Missouri-ColumbiaRecruitingGlucose Metabolism Disorders | Metabolic Syndrome | Metabolic Syndrome, Protection AgainstUnited States
-
Mayo ClinicCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
Clinical Trials on Bread types
-
Maastricht UniversityWageningen UniversityCompleted
-
Glycemic Index Laboratories, IncUniversity of Guelph; Guelph Research and Development Centre, Agriculture and...Completed
-
Paulic Meunerie SAInstitut Polytechnique UniLaSalleCompleted
-
University College CorkUniversity College DublinCompletedVitamin D DeficiencyIreland
-
University of Eastern FinlandVTT Technical Research Centre of FinlandCompletedGlucose Metabolism Disorders | Inflammation | Intestinal Disorder
-
Arizona State UniversityCompletedInsulin ResistanceUnited States
-
KU LeuvenCompletedAppetite Regulation | Energy IntakeBelgium
-
Newcastle-upon-Tyne Hospitals NHS TrustBiotechnology and Biological Sciences Research CouncilCompleted
-
West German Center of Diabetes and HealthBakery HinkelCompleted
-
University of AberdeenCompletedHealthy | OverweightUnited Kingdom